First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Treatment with the (ADP-ribose) polymerase (PARP) inhibitor olaparib led to a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) vs physician’s choice of new hormonal agent (NHA) enzalutamide or abiraterone + prednisone in men with advanced prostate cancer harbouring certain gene mutations that were identified through genetic testing, the PROfound* trial has shown.
Treatment with durvalumab with or without tremelimumab appeared to improve overall survival (OS) in Asian patients with metastatic non-small cell lung cancer (mNSCLC) compared with chemotherapy (CT) in the first-line setting, according to a post hoc analysis of the MYSTIC* trial presented at ESMO Asia 2019.
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
First-line treatment with durvalumab + platinum-etoposide (EP)* improves overall survival (OS) in Asian patients with extensive-stage small-cell lung cancer (ES-SCLC), according to the CASPIAN** study.
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
C-reactive protein/albumin ratio (CAR) can provide prognostic information on survival in pancreatic cancer, such that patients with high pretreatment CAR may have poorer overall survival, according to a study presented at the ESMO Asia 2019 Congress.
The trastuzumab biosimilar HLX02 was equivalent to the reference trastuzumab in terms of overall response rate (ORR) in women with HER2*-positive (HER2+) breast cancer, along with similar safety profile, reveals a study presented at ESMO Asia 2019.
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.